International Journal of Pharmaceutical Sciences and Drug Analysis
  • Printed Journal
  • Refereed Journal
  • Peer Reviewed Journal

P-ISSN: 2788-9246, E-ISSN: 2788-9254
Printed Journal   |   Refereed Journal   |   Peer Reviewed Journal

International Journal of Pharmaceutical Sciences and Drug Analysis

2022, Vol. 2, Issue 2, Part A

Clinical studies based potent drug therapy of 7-chloro-4-(Diethylamino)-1-methylbutyl amino quinidine and 2-[4-[(7-chloroquinolin-4-yl) amino]pentyl]-ethylamino ethanol for treatment of COVID-19 patients


Author(s): Vidhan C Bala, Minakshi B Ganguli, Nadir Khan and Robinsh Kumar

Abstract: Coronavirus 2 (Severe acute respiratory syndrome coronavirus 2), can also be a rapidly emerging infection that causes coronavirus disease 2019 (COVID-19). 4QAs have gained unprecedented attention as a potential therapeutic agent against COVID-19 after numerous small clinical trials and uncontrolled case series and name recall. While there is a growing body of scientific data, there's also a priority for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we conduct a quick narrative review and discuss the strengths and limitations of existing laboratory and clinical studies. We use evidence from additional randomized controlled trials prior to the broad incorporation of 4QAs into national and international treatment guidelines.

Pages: 10-21 | Views: 26 | Downloads: 11

Download Full Article: Click Here
How to cite this article:
Vidhan C Bala, Minakshi B Ganguli, Nadir Khan, Robinsh Kumar. Clinical studies based potent drug therapy of 7-chloro-4-(Diethylamino)-1-methylbutyl amino quinidine and 2-[4-[(7-chloroquinolin-4-yl) amino]pentyl]-ethylamino ethanol for treatment of COVID-19 patients. Int J Pharm Sci Drug Anal 2022;2(2):10-21.
International Journal of Pharmaceutical Sciences and Drug Analysis